ecrin-mdr-crcClinical2017Colorectal cancer metastaticMetastatisk, ikke-resektabel og kemo-refraktær kolorektal-kræftMetastatic, non-resectable and chemo-refractory colorectal cancerMetastatisk, Ikke-resektabel Og Kemo-refraktær Kolorektal-kræftMetastatic, Non-resectable And Chemo-refractory Colorectal CancerColorectal Cancer MetastaticInterventionalhttps://newmdr.ecrin.org/Study/2536542Denmark4LonsurfAvastinECRIN MDRCompletedfalseLonsurf - RII Lonsurf (TAS-102) with or without bevacizumab in patients with chemo-refractory metastatic colorectal cancer. A randomized phase II studyPrimary objective: • Progression-free survival (PFS) Primary end-point: • Progression-free survival (PFS)2017-04-1525365422016-005241-23